- Bicycle Therapeutics to Participate in the Jefferies Healthcare Conference
- Bicycle Therapeutics and Orano Med Present Preclinical Bicycle® Radio-Conjugate Data at TIDES 2023
- Bayer and Bicycle Therapeutics Enter Strategic Collaboration for Development of Novel Targeted Radionuclide Therapies in Oncology
- Bicycle Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
- Bicycle Therapeutics Announces Collaboration With the German Cancer Research Center, to Discover and Develop Wholly Owned Bicycle® Radio Conjugates for a Range of Oncology Targets
- Bicycle Therapeutics to Present at the 2023 AACR Annual Meeting
- Bicycle Therapeutics Enhances Leadership Team with Key Appointments
- Bicycle Therapeutics Announces a Strategic Collaboration with Novartis to Discover, Develop and Commercialize Bicycle® Radio-Conjugates
More ▼
Key statistics
On Tuesday, Bicycle Therapeutics PLC (BCYC:NSQ) closed at 25.53, -23.77% below its 52-week high of 33.49, set on Dec 14, 2022.
52-week range
Open | 25.83 |
---|---|
High | 26.15 |
Low | 24.70 |
Bid | -- |
Offer | -- |
Previous close | 25.53 |
Average volume | 155.65k |
---|---|
Shares outstanding | 30.04m |
Free float | 4.33m |
P/E (TTM) | -- |
Market cap | 767.01m USD |
EPS (TTM) | -4.17 USD |
Data delayed at least 15 minutes, as of Jun 06 2023 21:00 BST.
More ▼